1. Scrip
  2. >>Business
  3. >>Deals

What next for acquisition-hungry Valeant?

 
• By Sukaina Virji

Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time to do a post mortem," according to Laurie Little, Valeant's VP of investor relations, speaking at the Jefferies Global Healthcare Conference on 19 November. However, there's "no urgency" to get another big deal going. "We need a few days' rest," she said. "It would be good to string a few quiet quarters together."

Valeant Pharmaceuticals' CEO J Michael Pearson was in Asia when the news broke at the start of this week that Valeant had lost out to Actavis in its bid for Allergan. As a result, "We haven't had time to do a post mortem," according to Laurie Little, Valeant's VP of investor relations, speaking at the Jefferies Global Healthcare Conference on 19 November. However, there's "no urgency" to get another big deal going. "We need a few days' rest," she said. "It would be good to string a few quiet quarters together."

But of course, this is Valeant, and Ms Little acknowledged that Valeant's business development team was "active" even while Allergan...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Xu Hu

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.